🔗 Permalink

Inventor profile of:

Jon E. Chatterton

City:

Fort Worth, Texas

Country:

United States

Published Applications:

Last publication date:

2022-11-17

Top Assignees for applications by Jon E. Chatterton

The entities that hold a legal rights for patent applications filed by inventor Chatterton Jon E.:

ALCON RESEARCH, LTD. 40 Fort Worth, TX United States
ARROWHEAD RESEARCH CORPORATION 6 Pasadena, CA United States
Arrowhead Pharmaceuticals, Inc. 5 Pasadena, CA United States
NOVARTIS AG 2 Basel, Switzerland
THERMO FISHER SCIENTIFIC BIOSCIENCES INC. 2 Lafayette, CO United States
Alcon, Inc. 2 Hunenberg, Switzerland
Arrowhead Pharmaceuticals 1 Pasadena, CA United States
Dharmacon, Inc. 1 Lafayette, CO United States
Novartis, AG 1 , Switzerland
Thermo Fisher Scientific Inc. 1 Waltham, MA United States
Arrowhead Research Corporation 1 Madison, WI United States

Recent patent applications by Chatterton Jon E.

Jon E. Chatterton from Fort Worth, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2022-11-17

US20220364097A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#2 | 2022-05-26

US20220162614A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#3 | 2022-02-10

US20220042021A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#4 | 2021-07-29

US20210230603A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#5 | 2021-04-15

US20210108206A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#6 | 2020-12-17

US20200392508A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#7 | 2020-09-03

US20200277608A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#8 | 2020-05-28

US20200165615A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#9 | 2020-02-13

US20200048637A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#10 | 2019-11-07

US20190338287A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#11 | 2019-08-22

US20190256854A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#12 | 2019-05-16

US20190144866A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#13 | 2019-03-07

US20190071676A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#14 | 2017-07-13

US20170198294A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#15 | 2017-05-25

US20170145415A1

Chemistry; metallurgy

Transferrin/transferrin receptor-mediated siRNA delivery

#16 | 2017-02-23

US20170051291A1

Chemistry; metallurgy

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders

#17 | 2016-09-08

US20160257963A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS

#18 | 2016-09-08

US20160257956A1

Chemistry; metallurgy

Interfering RNA delivery system and uses thereof

#19 | 2016-04-07

US20160095937A1

Human necessities

Interfering RNA delivery system and uses thereof

#20 | 2016-02-25

US20160053270A1

Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

#21 | 2015-11-05

US20150315592A1

Chemistry; metallurgy

Transferrin/transferrin receptor-mediated siRNA delivery

#22 | 2014-12-04

US20140357695A1

Chemistry; metallurgy

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

#23 | 2014-07-10

US20140194359A1

Chemistry; metallurgy

Interfering RNA delivery system and uses thereof

#24 | 2014-05-15

US20140135267A1

Human necessities

Interfering RNA delivery system and uses thereof

#25 | 2014-03-27

US20140088172A1

Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

#26 | 2014-03-18

US12580663

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders

#27 | 2014-01-30

US20140031414A1

Chemistry; metallurgy

siRNA targeting VEGFA and methods for treatment in vivo

#28 | 2014-01-16

US20140018296A1

Human necessities

Low density lipoprotein receptor-mediated siRNA delivery

#29 | 2013-12-19

US20130338213A1

Human necessities

RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS

#30 | 2013-09-19

US20130245098A1

Chemistry; metallurgy

RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis

#31 | 2013-07-11

US20130178421A1

Human necessities

INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF

#32 | 2013-07-11

US20130177580A1

Human necessities

Transferrin/transferrin receptor-mediated siRNA delivery

#33 | 2012-12-13

US20120315288A1

Chemistry; metallurgy

Low density lipoprotein receptor-mediated siRNA delivery

#34 | 2012-10-18

US20120264809A1

Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

#35 | 2012-09-27

US20120245217A1

Chemistry; metallurgy

RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis

#36 | 2012-07-12

US20120178795A1

Chemistry; metallurgy

RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

#37 | 2012-07-12

US20120178794A1

Chemistry; metallurgy

RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders

#38 | 2012-03-29

US20120077864A1

Human necessities

RNAI-MEDIATED INHIBITION OF GREMLIN FOR TREATMENT OF IOP-RELATED CONDITIONS

#39 | 2012-02-02

US20120029051A1

Chemistry; metallurgy

siRNA targeting VEGFA and methods for treatment in vivo

#40 | 2011-11-24

US20110288157A1

Chemistry; metallurgy

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

#41 | 2011-11-03

US20110269822A1

Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

#42 | 2011-10-20

US20110257248A1

Chemistry; metallurgy

RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis

#43 | 2011-10-20

US20110257246A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS

#44 | 2011-10-20

US20110256156A1

Chemistry; metallurgy

Transferrin/transferrin receptor-mediated siRNA delivery

#45 | 2011-10-06

US20110245319A1

Chemistry; metallurgy

RNAi-mediated inhibition of Rho kinase for treatment of ocular disorders

#46 | 2011-09-22

US20110230410A1

Chemistry; metallurgy

Low density lipoprotein receptor-mediated siRNA delivery

#47 | 2011-08-04

US20110190381A1

Chemistry; metallurgy

RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

#48 | 2011-08-04

US20110190376A1

Chemistry; metallurgy

RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA

#49 | 2011-07-05

US12244027

Transferrin/transferrin receptor-mediated siRNA delivery

#50 | 2011-06-16

US20110142767A1

Chemistry; metallurgy

RNAi-mediated inhibition of tumor necrosis factor α-related conditions

#51 | 2011-06-09

US20110135579A1

Chemistry; metallurgy

RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma

#52 | 2011-05-26

US20110124708A1

Chemistry; metallurgy

RNAI-MEDIATED INHIBITION OF OCULAR HYPERTENSION TARGETS

#53 | 2011-04-07

US20110082092A1

Human necessities

Interfering RNA delivery system and uses thereof

#54 | 2010-12-02

US20100305193A1

Human necessities

RNAI-MEDIATED INHIBITION OF GREMLIN FOR TREATMENT OF IOP-RELATED CONDITIONS

#55 | 2010-10-21

US20100267811A1

Chemistry; metallurgy

RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS

#56 | 2010-07-01

US20100166676A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS

#57 | 2010-06-10

US20100144844A1

Chemistry; metallurgy

RNAi-mediated inhibition of H1F1A for treatment of ocular angiogenesis

#58 | 2009-12-31

US20090326044A1

Chemistry; metallurgy

RNAi-Mediated Inhibition of Ocular Targets

#59 | 2009-12-31

US20090324507A1

Chemistry; metallurgy

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

#60 | 2009-11-05

US20090275641A1

Chemistry; metallurgy

RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders

#61 | 2009-11-05

US20090274631A1

Chemistry; metallurgy

RNAi-mediated inhibition of histamine receptor H1-related conditions

#62 | 2009-08-20

US20090209627A1

Chemistry; metallurgy

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

#63 | 2009-06-18

US20090156470A1

Human necessities

Interfering RNA delivery system and uses thereof

#64 | 2009-04-23

US20090105182A1

Chemistry; metallurgy

RNAi-MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR 1-RELATED TARGETS FOR TREATMENT OF NEOVASCULARIZATION-RELATED CONDITIONS

InventorID:

334188 ⎘